These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 78645

  • 1. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
    Agrup G, Hansson C, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
    [Abstract] [Full Text] [Related]

  • 2. Protein-bound dopa and 5-S-cysteinyldopa in non-melanogenic tissues.
    Ito S, Jimbow K, Kato T, Kiyota M, Fujita K.
    Acta Derm Venereol; 1983; 63(6):463-7. PubMed ID: 6198833
    [Abstract] [Full Text] [Related]

  • 3. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
    Morishima T, Tatsumi F, Fukada E, Watanabe M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
    Agrup G, Falck B, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
    [Abstract] [Full Text] [Related]

  • 7. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G, Agrup P, Andersson T, Falck B, Hansson JA, Jacobsson S, Rorsman H, Rosengren E, Rosengren AM.
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, Jönsson PE, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M, Mojamdar M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
    Morishima T, Saito M, Fujita M, Fukada E, Nagashima N, Hanawa S.
    Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. gamma-Glutamyl transpeptidase, tyrosinase, and 5-S-cysteinyldopa production in melanoma cells.
    Mojamdar M, Ichihashi M, Mishima Y.
    J Invest Dermatol; 1983 Aug; 81(2):119-21. PubMed ID: 6135733
    [Abstract] [Full Text] [Related]

  • 20. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983 Aug; 275(2):76-9. PubMed ID: 6409012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.